Clinical Trials Browser

Phase 1/2 × Active not recruiting × Dacarbazine × Clear all

NCT03033914 2026-02-17

A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)

Phase 1/2 Active not recruiting

Hodgkin Disease

NCT02979522 2025-11-10

A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma

Phase 1/2 Active not recruiting

59 enrolled 63 charts

Hodgkin Disease